Canaccord Genuity Downgrades ChemoCentryx to Hold, Announces $52 Price Target
Benzinga Newsdesk 4 years ago
NewsDowngradesPrice TargetAnalyst Ratings
Canaccord Genuity analyst Edward Nash downgrades ChemoCentryx (NASDAQ:CCXI) from Buy to Hold and announces $52 price target.
Canaccord Genuity analyst Edward Nash downgrades ChemoCentryx (NASDAQ:CCXI) from Buy to Hold and announces $52 price target.